Cancers, Vol. 13, Pages 1920: The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
Cancers doi: 10.3390/cancers13081920
Authors: Ruben Van Dijck Jeanette K. Doorduijn Jacoline E.C. Bromberg
Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου